Dose-Dependent Influence of RBD-Derived Amyloidogenic Peptides on SARS-CoV-2 Infectivity: A Cautionary Tale for Antiviral Design.

Dose-Dependent Influence of RBD-Derived Amyloidogenic Peptides on SARS-CoV-2 Infectivity: A Cautionary Tale for Antiviral Design.

Publication date: Jul 28, 2026

The receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein remains a central target for antiviral drug development. Recent in silico studies have revealed an expansion of amyloidogenic regions within the RBD of the Omicron variant, raising the possibility that amyloid-prone peptide fragments could modulate Spike function or host-virus interactions. In this study, we combined experimental assays with multiscale computational modeling to systematically characterise two short RBD-derived peptides: Pep-2 (YFPLQSYGFQ) from the ancestral Wuhan strain and Pep-3 (YFPLRSYSFR) from the Omicron BA. 1 variant, the latter being predicted to have higher amyloidogenic potential. Cell-based assays demonstrated that neither peptide exhibited intrinsic cytotoxic or cytostatic effects on human lung fibroblasts or A549 lung adenocarcinoma cells at physiologically relevant concentrations, whereas significant cytotoxicity was observed in Vero E6 cells. In infection models with the B. 1.1. 1 (Wuhan) and BA. 1 (Omicron) variants, the peptides unexpectedly enhanced virus-induced cytopathic effects at lower concentrations but inhibited viral infection at higher concentrations, indicating to a dose-dependent modulatory role for these short amyloidogenic RBD fragments. Fluorescence spectroscopy measurements did not detect the formation of stable thioflavin-T-positive amyloid fibrils. Computational analyses revealed that both peptides interact with the Spike RBD via multiple energetically favorable yet spatially heterogeneous modes, mostly outside the ACE2-binding site. Moreover, their predicted binding affinities for the ACE2 receptor were comparable, suggesting an additional route of interaction via the host receptor. Collectively, our findings demonstrate that these short amyloidogenic RBD-derived peptides exert a complex antiviral profile, with their interactions with both viral and host factors potentially shaping infection outcomes. This highlights the importance of spatially targeted and conformationally constrained peptide designs to effectively harness amyloidogenic features for antiviral therapy.

Open Access PDF

Concepts Keywords
A549 A549 Cells
Amyloidogenic amyloidogenic properties
Antiviral Amyloidogenic Proteins
Spectroscopy Amyloidogenic Proteins
Viral Animals
Antiviral Agents
Antiviral Agents
Chlorocebus aethiops
COVID-19
Drug Design
Humans
molecular modelling
Omicron variant
Peptide Fragments
Peptide Fragments
Peptides
Peptides
Protein Binding
receptor-binding domain (RBD)
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
Spike protein
spike protein, SARS-CoV-2
Vero Cells

Semantics

Type Source Name
disease MESH strain
disease MESH lung adenocarcinoma
disease MESH infection
disease MESH viral infection
drug DRUGBANK Coenzyme M
drug DRUGBANK Angiotensin II
disease MESH face
disease MESH tic
disease MESH SARS CoV 2 infection
drug DRUGBANK Tromethamine
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Acetic acid
pathway KEGG Virion
drug DRUGBANK Trestolone
disease MESH dissociation
drug DRUGBANK Water
drug DRUGBANK Aspartame
drug DRUGBANK Zinc
drug DRUGBANK Calusterone
disease MESH CLS
drug DRUGBANK Cefaclor
disease MESH CCL
disease MESH FBS
disease MESH mycoplasma infection
drug DRUGBANK Gentian violet cation
disease MESH dis
disease MESH included
drug DRUGBANK Rasagiline
drug DRUGBANK Isoxaflutole
pathway REACTOME Antimicrobial peptides
disease MESH HIV Infection
pathway REACTOME HIV Infection
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH injury

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *